Soleno Therapeutics Acquired by Neurocrine Biosciences | Healthcare M&A Deal

Neurocrine Biosciences has acquired Soleno Therapeutics, a pharmaceuticals business in California, for $53.00 per share. Soleno Therapeutics is a biopharmaceutical company focused on developing therapies, and Neurocrine Biosciences acquisitions expand its healthcare M&A footprint in CA acquisitions. The merger acquisition is structured as a strategic acquisition through a wholly owned subsidiary tender offer, with Neurocrine Biosciences acquiring all outstanding Soleno common stock. The healthcare deals CA are valued at over $100M and are governed by a cash tender offer under SEC Schedule TO, with the offer price payable in cash subject to withholding taxes.